Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
04:05pm, Wednesday, 02'nd Oct 2024
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of grow
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
07:05am, Tuesday, 01'st Oct 2024
Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications Non-exclusive license includes
Codexis Announces New Employment Inducement Grants
04:05pm, Friday, 06'th Sep 2024
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as app
Codexis to Participate in Upcoming Healthcare Conferences
04:05pm, Tuesday, 03'rd Sep 2024
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor c
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
04:05pm, Tuesday, 20'th Aug 2024
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel dis
Codexis Announces New Employment Inducement Grants
04:05pm, Friday, 16'th Aug 2024
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as appr
Codexis Publishes FY2023 Sustainability Disclosures
04:05pm, Thursday, 15'th Aug 2024
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript
11:01pm, Thursday, 08'th Aug 2024
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research K
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th Aug 2024
Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago.
Codexis to Report Second Quarter 2024 Financial Results on August 8
04:05pm, Thursday, 18'th Jul 2024
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second qua
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
04:05pm, Monday, 01'st Jul 2024
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswa
Codexis to Participate in Jefferies Global Healthcare Conference
04:25pm, Wednesday, 22'nd May 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Confe
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
04:05pm, Monday, 20'th May 2024
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, �
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
06:00am, Tuesday, 14'th May 2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enz
Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript
08:24pm, Thursday, 02'nd May 2024
Codexis, Inc. (NASDAQ:CDXS ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Office
